Market access
We help life sciences companies successfully initiate and sustain product commercialization at each point along the continuum.
Why choose us?
A trusted partner in an increasingly complex launch environment
The journey from research and development through product launch is seldom straightforward and never guaranteed.
The inherent complexities of market entry are being compounded by new variables, including coverage-with-evidence requirements, shifting sales models, and Medicare drug price negotiation, among other factors.
Reducing go-to-market risk requires heightened coordination across the organization and significant business model adjustments, while proof points of safety and efficacy must be augmented by evidence of value.
Our approach
A partner at every stage
Our cross-functional team partners with life sciences companies to deliver expert guidance at each point along the access and commercialization continuum.
At the outset, we’ll help assess the burden of illness, identify treatment gaps, and conduct market sizing. We can then design clinical studies and calculate value and cost-avoidance projections. Pre-launch, we will work with you to develop appropriate pricing, assist with payer and provider segmentation, gauge the regulatory and policy landscape, and implement the optimal distribution approach. The latter step can include navigating logistical challenges associated with direct-to-patient distribution for novel therapeutics.
Our post-launch support includes optimizing patient identification and the patient journey, real-world evidence generation and dissemination, registry development, price modeling, value messaging, and customer communication.
Market access strategic plan
Who we help
Biopharma drug manufacturers
Medical device and diagnostic manufacturers
Digital therapeutics manufacturers
Retail and specialty pharmacies
Provider groups
Trade organizations
Offerings
Market access analytics
Reimbursement assessment and strategy
Commercial launch readiness
FDA and regulatory filing strategy
Pricing strategy
Patient access and support services
Our work
How we have helped clients
Case study
Product utilization data and analysis informs biotech growth strategy
A biotechnology company sought detailed product utilization data, by indication and line of therapy, and commercialization strategy support to improve access to its product. We leveraged our in-house claims data to assess the size and utilization patterns of the patient populations of interest, analyzing Part B claims data and translating analytic findings into actionable commercialization strategies. We developed visuals to convey the results of our analysis, which the client is using to better understand utilization trends and inform its growth strategy.
Discover moreCase study
Forecasting global value assessments for a rare disease drug launch
We helped an emerging biotechnology company develop a multi-national pricing and commercialization strategy for a drug to treat an ultra-rare neurodegenerative disorder. The client sought our expertise in determining how payers in priority markets would assess the product’s value given clinical trial data (e.g., endpoints and patient groups), product characteristics, and market dynamics in each country of interest (i.e., US, EU, UK, Canada, Australia, and Japan). We reviewed published literature on the indication, conducted a coverage and reimbursement landscape analysis for each target market, and convened advisory board meetings among US and global payers to strengthen the client’s pricing and commercialization strategy.
Discover moreCase study
Comprehensive pre-launch planning for a competitive novel vaccine
We conducted primary and secondary market research, qualitative evidence assessments, quantitative conjoint analyses, and in-depth stakeholder interviews to help develop pricing and commercialization strategies for a novel vaccine preparing to launch against a competitor product.
Discover more
Our people
